<DOC>
	<DOC>NCT00402948</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers . The study will also look at the nature and quantity of inflammatory white cells in the lung secretions and in the blood, and some additional inflammation markers.</brief_summary>
	<brief_title>Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients</brief_title>
	<detailed_description>See above</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 1865 y. old, non or exsmokers for &gt; 6 months Mild to moderate asthmatic in general good health On either lowdose inhaled corticosteroid or steroid naive No other asthma medication Regular sputum producer EOS more than 3% at randomization, FEV1 &gt; 70% Respiratory infection within last 4 weeks Any condition that may affect the conduct of the study as per the investigators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>High eosinophils level in sputum</keyword>
</DOC>